> top > docs > PubMed:22901458 > annotations

PubMed:22901458 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-77 Sentence denotes Fatigue in ankylosing spondylitis: treatment should focus on pain management.
T2 78-89 Sentence denotes OBJECTIVES:
T3 90-166 Sentence denotes Fatigue is an important symptom associated with ankylosing spondylitis (AS).
T4 167-310 Sentence denotes This study examines patients' perspectives and clinical associations of fatigue to help inform potential strategies to alleviate fatigue in AS.
T5 311-319 Sentence denotes METHODS:
T6 320-404 Sentence denotes A mixed methods approach was taken to examine fatigue in a cohort of people with AS.
T7 405-477 Sentence denotes Fatigue levels were evaluated from 3 consecutive monthly questionnaires.
T8 478-610 Sentence denotes Open-ended questions on fatigue were analyzed using thematic analysis and logistic regression was used to examine quantitative data.
T9 611-750 Sentence denotes In addition, fatigue levels were examined before and after treatment with anti-tumor necrosis factor (TNF) compared to nontreated controls.
T10 751-759 Sentence denotes RESULTS:
T11 760-840 Sentence denotes Three hundred forty-eight of 385 participants completed a fatigue questionnaire.
T12 841-926 Sentence denotes Fatigue was reported to have significant physical, social, and psychological effects.
T13 927-1108 Sentence denotes A third of the participants reported that there was nothing they could do to reduce their fatigue, whereas other participants reported that medication, exercise, and resting helped.
T14 1109-1173 Sentence denotes The main factor associated with fatigue was pain [β-coefficient:
T15 1174-1187 Sentence denotes 0.74 (95% CI:
T16 1188-1257 Sentence denotes 0.66 to 0.81)], whereas depression was much less strongly associated.
T17 1258-1335 Sentence denotes However, these factors only explained 40% of the variation in fatigue levels.
T18 1336-1460 Sentence denotes Starting anti-TNF therapy reduced fatigue and pain levels compared to the period of time before taking anti-TNF [difference:
T19 1461-1474 Sentence denotes 14.4 (95% CI:
T20 1475-1574 Sentence denotes 5.3 to 23.5) on a scale of 0-100] and this reduction was not seen in controls over the same period.
T21 1575-1587 Sentence denotes CONCLUSIONS:
T22 1588-1721 Sentence denotes Fatigue is not strongly associated with anxiety, motivation, and depression; instead the factor most associated with fatigue is pain.
T23 1722-1914 Sentence denotes This suggests that in addition to treatments to reduce disease activity, strategies for alleviating fatigue in AS should focus on pain management techniques and actively treating inflammation.
T1 0-77 Sentence denotes Fatigue in ankylosing spondylitis: treatment should focus on pain management.
T2 78-89 Sentence denotes OBJECTIVES:
T3 90-166 Sentence denotes Fatigue is an important symptom associated with ankylosing spondylitis (AS).
T4 167-310 Sentence denotes This study examines patients' perspectives and clinical associations of fatigue to help inform potential strategies to alleviate fatigue in AS.
T5 311-319 Sentence denotes METHODS:
T6 320-404 Sentence denotes A mixed methods approach was taken to examine fatigue in a cohort of people with AS.
T7 405-477 Sentence denotes Fatigue levels were evaluated from 3 consecutive monthly questionnaires.
T8 478-610 Sentence denotes Open-ended questions on fatigue were analyzed using thematic analysis and logistic regression was used to examine quantitative data.
T9 611-750 Sentence denotes In addition, fatigue levels were examined before and after treatment with anti-tumor necrosis factor (TNF) compared to nontreated controls.
T10 751-759 Sentence denotes RESULTS:
T11 760-840 Sentence denotes Three hundred forty-eight of 385 participants completed a fatigue questionnaire.
T12 841-926 Sentence denotes Fatigue was reported to have significant physical, social, and psychological effects.
T13 927-1108 Sentence denotes A third of the participants reported that there was nothing they could do to reduce their fatigue, whereas other participants reported that medication, exercise, and resting helped.
T14 1109-1173 Sentence denotes The main factor associated with fatigue was pain [β-coefficient:
T15 1174-1187 Sentence denotes 0.74 (95% CI:
T16 1188-1257 Sentence denotes 0.66 to 0.81)], whereas depression was much less strongly associated.
T17 1258-1335 Sentence denotes However, these factors only explained 40% of the variation in fatigue levels.
T18 1336-1460 Sentence denotes Starting anti-TNF therapy reduced fatigue and pain levels compared to the period of time before taking anti-TNF [difference:
T19 1461-1474 Sentence denotes 14.4 (95% CI:
T20 1475-1574 Sentence denotes 5.3 to 23.5) on a scale of 0-100] and this reduction was not seen in controls over the same period.
T21 1575-1587 Sentence denotes CONCLUSIONS:
T22 1588-1721 Sentence denotes Fatigue is not strongly associated with anxiety, motivation, and depression; instead the factor most associated with fatigue is pain.
T23 1722-1914 Sentence denotes This suggests that in addition to treatments to reduce disease activity, strategies for alleviating fatigue in AS should focus on pain management techniques and actively treating inflammation.

Allie

Id Subject Object Predicate Lexical cue
SS1_22901458_2_0 138-160 expanded denotes ankylosing spondylitis
SS2_22901458_2_0 162-164 abbr denotes AS
SS1_22901458_8_0 685-711 expanded denotes anti-tumor necrosis factor
SS2_22901458_8_0 713-716 abbr denotes TNF
AE1_22901458_2_0 SS1_22901458_2_0 SS2_22901458_2_0 abbreviatedTo ankylosing spondylitis,AS
AE1_22901458_8_0 SS1_22901458_8_0 SS2_22901458_8_0 abbreviatedTo anti-tumor necrosis factor,TNF

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 90-97 HP_0012378 denotes Fatigue
T2 239-246 HP_0012378 denotes fatigue
T3 296-303 HP_0012378 denotes fatigue

Wangshuguang

Id Subject Object Predicate Lexical cue
T1 114-121 B-Variation denotes symptom
T2 561-571 B-Variation denotes regression
T3 572-575 B-Regulation denotes was
T4 576-580 I-Regulation denotes used
T5 584-591 B-Negative_Regulation denotes examine
T6 853-861 B-Regulation denotes reported
T7 862-864 I-Regulation denotes to
T8 865-869 I-Regulation denotes have
T9 1067-1077 B-Variation denotes medication
T10 1410-1416 B-Molecular_Activity denotes period
T11 1518-1527 B-Variation denotes reduction
T12 1544-1552 B-Variation denotes controls
T13 1567-1573 B-Variation denotes period
T14 1822-1829 B-Variation denotes fatigue
T15 1914-1914 B-Variation denotes

123123123

Id Subject Object Predicate Lexical cue
T1 114-121 B-Variation denotes symptom
T2 561-571 B-Variation denotes regression
T3 572-575 B-Regulation denotes was
T4 576-580 I-Regulation denotes used
T5 584-591 B-Negative_Regulation denotes examine
T6 853-861 B-Regulation denotes reported
T7 862-864 I-Regulation denotes to
T8 865-869 I-Regulation denotes have
T9 1067-1077 B-Variation denotes medication
T10 1410-1416 B-Molecular_Activity denotes period
T11 1518-1527 B-Variation denotes reduction
T12 1544-1552 B-Variation denotes controls
T13 1567-1573 B-Variation denotes period
T14 1822-1829 B-Variation denotes fatigue
T15 1914-1914 B-Variation denotes